Skip to content
StackItSmart
DPreclinical / mechanistic only
No human data

BPC-157

Body Protection Compound 157

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide (pentadecapeptide) derived from a fragment of a protein found in human gastric juice. It is marketed within fitness, "biohacking," and injury-recovery communities as a healing/regenerative agent for tendon, ligament, muscle, and gut injuries. The single most important thing to understand is that essentially all of the widely cited benefits come from rat and in-vitro studies, most from one research group. There is no adequate controlled human data: no completed Phase II trial, no approved formulation, no validated human dose, and human evidence is limited to fewer than ~30 people across small uncontrolled pilots plus a 17-patient retrospective knee chart review. The human safety profile is essentially uncharacterized (long-term toxicity, cancer risk, and cardiovascular effects in humans are unknown), and because BPC-157 is a potent promoter of blood-vessel growth (angiogenesis) in animals, there is a theoretical concern it could feed tumor growth, untested in humans. Product sold as "BPC-157" is unregulated and unapproved for human use, so identity, purity, sterility, and contamination are unverifiable. It is also prohibited in sport by WADA. Treat all efficacy claims as unproven in humans.

Clinical readoutPeptide · healing-peptide
Hepatic strainNone
CardiovascularModerate
HPTA suppressionNone
Half-life
30 min
Route
Studied in animals via…
Evidence
D
Active
A notable pharmacokinet…
30 min1 h1.5 h2 h2.5 h
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Short. A formal preclinical ADME study in two species and a preliminary two-subject human pilot indicate a plasma half-life of under ~30 minutes; human PK is otherwise essentially uncharacterized.
Pharmacology

Mechanism of action

Proposed mechanisms are derived almost entirely from animal and cell studies. BPC-157 is reported to promote angiogenesis (new blood-vessel formation) and to up-regulate vascular endothelial growth factor (VEGF) signaling and the VEGFR2-Akt-eNOS pathway, increasing local nitric oxide availability and blood flow to injured tissue. It interacts with the nitric oxide (NO) system and appears to counteract effects of NO-synthase blockade. In vessel-occlusion rat models it is described as rapidly activating collateral (bypass) blood-flow pathways. It is also reported to modulate growth-factor and cytokine expression (e.g., EGR-1, FAK-paxillin), influence the dopaminergic and serotonergic systems when given peripherally, and stabilize gut mucosa (a proposed mediator of "cytoprotection"). None of these mechanisms has been confirmed to operate meaningfully at achievable exposures in humans.
Kinetics

Pharmacokinetics

Half-life

Short. A formal preclinical ADME study in two species and a preliminary two-subject human pilot indicate a plasma half-life of under ~30 minutes; human PK is otherwise essentially uncharacterized.

Active duration

A notable pharmacokinetic-pharmacodynamic disconnect is reported: despite a sub-30-minute plasma half-life, biological effects in animal models are described as lasting hours to days. The true duration of any effect in humans is unknown.

Route

Studied in animals via oral, intramuscular, intraperitoneal, subcutaneous, and topical routes; reported IM bioavailability was ~14-51% depending on species. Community use is typically subcutaneous or intramuscular injection or oral. No pharmaceutical-grade, validated human formulation exists.

Metabolism & clearance

As a small peptide it is expected to undergo proteolytic (enzyme) breakdown into constituent amino acids; it is reported to be unusually stable in gastric juice. Detailed human metabolism and clearance/excretion pathways are not established. PK data here are for washout/monitoring and clinician discussion only, not for evading drug testing.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Reported in animal models to accelerate healing of tendon, ligament, muscle, bone, and skin wounds (not confirmed in controlled human studies)
  • Reported gastrointestinal mucosal protection and healing of ulcers and fistulas in rats
  • Reported promotion of angiogenesis and activation of collateral blood-flow pathways in rat vascular-occlusion models
  • In a small uncontrolled retrospective human chart review (17 knee-pain patients), most patients reported subjective pain improvement after intra-articular injection - low-quality, uncontrolled evidence only
  • Older references cite small clinical trials in inflammatory bowel disease (PL-14736), but robust controlled outcome data are not established in the peer-reviewed literature
  • Human efficacy for any indication remains unproven
Safety

Adverse effects by system

Cardiovascular

No adequate human cardiovascular safety data. Because BPC-157 strongly modulates angiogenesis, VEGF/NO signaling, and blood pressure/blood flow in animal models, effects on human blood pressure and vasculature are plausible but entirely uncharacterized. Absence of reported harm reflects absence of study, not proven safety.

Hepatic

No adequate human data. Some rat models report hepatoprotective effects, but human hepatotoxicity has not been studied. Unknown.

Endocrine / HPTA

No known direct hormonal or hypothalamic-pituitary-gonadal (HPTA) axis suppression is described, and no human endocrine data exist. It is not an androgen or SERM and is not expected to suppress the HPTA, but this has not been formally evaluated in humans.

Reproductive

No human reproductive, fertility, pregnancy, or lactation safety data. Should be considered unsafe/contraindicated in pregnancy and breastfeeding by default. Unknown.

Neuropsychiatric

No adequate human data. Animal studies describe interactions with dopamine and serotonin systems and behavioral effects in rodents; whether this translates to any mood or psychiatric effect in humans is unknown.

Renal

No adequate human data. Some rat studies report protection against kidney injury; human renal safety is unstudied. Unknown.

Hematologic

No adequate human data. Effects on coagulation or blood counts in humans are unstudied; some animal work reports interaction with bleeding/clotting and vascular integrity, so effects are theoretically possible but uncharacterized.

Dermatologic

No systematic human data. As an injected, unregulated product the main practical dermatologic/soft-tissue risks are injection-site reactions, pain, bruising, and infection/abscess from non-sterile product or technique rather than a proven pharmacologic skin effect.

Recovery

HPTA suppression & recovery

Suppression: None expected / not characterized in humans

BPC-157 is a peptide, not an anabolic steroid or SERM, and there is no established mechanism or human evidence for hypothalamic-pituitary-gonadal (HPTA) axis suppression; therefore no post-cycle recovery protocol applies. This monograph does not describe or endorse any SERM-based recovery protocol. Anyone with concerns about hormonal status or fertility should have baseline and follow-up bloodwork and consult an endocrinologist. Single-SERM approaches only would ever be discussed for genuinely suppressive compounds; dual-SERM protocols are out of scope entirely.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline and periodic complete blood count (CBC)Comprehensive metabolic panel including liver enzymes (ALT/AST) and kidney function (creatinine/eGFR)Blood pressure monitoringLipid panelAge- and risk-appropriate cancer screening before and during use, given the pro-angiogenic mechanism

Cadence: Baseline before any use, then periodically (e.g., every 8-12 weeks) during use and if any new symptoms arise; all monitoring should be arranged and interpreted by a clinician. There is no validated, evidence-based monitoring schedule for this unapproved compound.

Warning signs — seek care
  • New or unusual lumps, rapidly changing moles, unexplained weight loss, or other possible cancer warning signs - stop and seek evaluation
  • Injection-site pain, redness, swelling, warmth, pus, or fever (possible infection/abscess)
  • Chest pain, palpitations, shortness of breath, or significant blood-pressure changes
  • Signs of allergic reaction (rash, swelling, difficulty breathing) - seek emergency care
  • Any unexpected bleeding or bruising
  • New neurological or mood changes
Do not use if

Contraindications

  • Pregnancy and breastfeeding (no safety data; avoid)
  • Active or prior cancer, or elevated cancer risk - theoretical concern that pro-angiogenic activity could support tumor blood supply (untested in humans)
  • Known or suspected active malignancy of any kind until discussed with an oncologist
  • Use of unregulated/research-grade or non-sterile product (risk of contamination, endotoxin, infection)
  • Any use in minors (under 21) or without medical oversight
  • Competitive athletes subject to anti-doping rules - BPC-157 is prohibited by WADA
  • Known hypersensitivity to the peptide or excipients/diluent
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Understand that human efficacy is unproven and human safety is essentially uncharacterized: nearly all evidence is from rats and cell cultures, largely from a single research group. Do not treat animal results as proof of human benefit or safety.
  • The biggest theoretical concern is cancer: BPC-157 promotes blood-vessel growth in animals, which could in principle support tumor growth. Anyone with a personal or strong family history of cancer should avoid it and discuss with an oncologist; stay current on age-appropriate cancer screening.
  • Products sold as BPC-157 are unapproved and unregulated - identity, purity, dose accuracy, sterility, and endotoxin content are unverifiable. Injecting non-sterile material risks infection, abscess, and endotoxin reactions.
  • Avoid entirely in pregnancy, breastfeeding, and in anyone under 21.
  • Do not use if you are a competitive athlete subject to anti-doping testing - BPC-157 is prohibited by WADA.
  • If you choose to use it despite the lack of human data, involve a physician, get baseline and follow-up bloodwork (CBC, liver, kidney, lipids) and blood-pressure checks, and use the lowest exposure for the shortest time.
  • Stop immediately and seek medical care for injection-site infection signs (spreading redness, pus, fever), chest pain or palpitations, allergic reactions, unexpected bleeding, or any new lump or possible cancer warning sign.
  • This is educational information only, not medical advice, and does not create a doctor-patient relationship. Consult a qualified physician before use.
Evidence

Citations (8)

Every clinical claim above is tied to a primary source. Overall evidence grade D — this compound lacks adequate human data; claims rest on preclinical or mechanistic evidence.

  1. 01

    BPC-157 is a synthetic pentadecapeptide derived from a human gastric-juice protein fragment, with over three decades of preclinical activity but no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial; available human data derive from fewer than ~30 subjects across three uncontrolled pilot studies.

    ReviewBPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.PMID 42198317 ↗

  2. 02

    Preclinical ADME in two species plus a preliminary two-subject human pilot indicate a plasma half-life under ~30 minutes with linear dose-proportional kinetics and IM bioavailability of ~14-51% depending on species, contrasting with prolonged (hours-to-days) biological effects - a pharmacokinetic-pharmacodynamic disconnect.

    ReviewBPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.PMID 42198317 ↗

  3. 03

    Studies of BPC-157 for musculoskeletal soft-tissue (tendon, ligament, skeletal muscle) healing report consistently positive effects, but the majority are small rodent studies and efficacy has not been confirmed in humans; few adverse reactions have been reported, though the healing mechanism and human safety remain to be established.

    PreclinicalGastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.PMID 30915550 ↗

  4. 04

    In a retrospective chart review of 17 patients receiving intra-articular BPC-157 for knee pain, most reported subjective improvement - uncontrolled, low-quality human evidence with no objective outcome measures.

    Case seriesIntra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.PMID 34324435 ↗

  5. 05

    BPC-157 exhibits cytoprotective/angiogenic activity, interacts with the nitric oxide system, promotes angiogenesis, and heals gastrointestinal and other lesions in rats; it is referenced as having been used in inflammatory bowel disease clinical trials (PL-14736), with mechanistic effects demonstrated in animal models.

    ReviewStable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response.PMID 17186181 ↗

  6. 06

    BPC-157 heals various external and internal gastrointestinal fistulas and improves anastomotic healing in rat models; described as native to and stable in human gastric juice, with LD1 not achieved in animals.

    PreclinicalFistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy.PMID 32329684 ↗

  7. 07

    BPC-157 is proposed as a potential agent against cancer cachexia based on animal evidence, with the authors explicitly framing this as preclinical evidence 'before clinical trial.'

    ReviewBPC157 as Potential Agent Rescuing from Cancer Cachexia.PMID 29898649 ↗

  8. 08

    BPC-157 normalizes intraocular pressure, protects retinal integrity, and counteracts vascular/occlusion syndromes in glaucomatous and injured rats by activating collateral blood-flow pathways - preclinical evidence only.

    PreclinicalStable Gastric Pentadecapeptide BPC 157-Possible Novel Therapy of Glaucoma and Other Ocular Conditions.PMID 37513963 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice